Prenatal market stress Rising pressure on prenatal testing with declining revenue from prenatal tests in H1 2024 and a strategic sale of the Prenatal Health testing business to Labcorp indicates a shift in portfolio focus. Sales opportunities exist in offering complementary diagnostic services, alternative assay workflows, or data analytics solutions to support prenatal testing strategies during this transition.

Strategic divestiture Myriad plans to divest its Prenatal Health testing unit for cash proceeds, signaling a potential openness to partner or license technology assets, APIs, or data platforms. Position as a collaborator for integrating or migrating Prenatal Health data, software, or instruments into a broader diagnostic ecosystem.

Research collaboration Active research partnerships and co-authored programs with AstraZeneca and SOPHiA GENETICS suggest a strong appetite for collaborative innovation. Explore opportunities to propose joint development projects, data-sharing initiatives, or precision medicine solutions leveraging Myriad’s genomic capabilities and partner networks.

Technology stack leverage Myriad employs a modern analytics and data infrastructure (Looker, Tableau, Snowflake, SAP, Informatica, Salesforce Lightning, Okta, etc.). Offer value through cloud-native data integration, real-time dashboards, security enhancements, and workflow automation tailored to genomic testing and clinical decision support.

Revenue optimization Recent revenue declines in prenatal testing and guidance lowering full-year revenue and margins point to a need for pricing strategy, payer negotiations, or alternative testing modalities. Propose value-based pricing, reimbursement optimization services, and diversified test portfolios to stabilize top-line growth.